Seres Therapeutics (MCRB) Current Leases: 2019-2025
Historic Current Leases for Seres Therapeutics (MCRB) over the last 7 years, with Sep 2025 value amounting to $9.9 million.
- Seres Therapeutics' Current Leases rose 18.86% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 18.86%. This contributed to the annual value of $8.7 million for FY2024, which is 55.25% up from last year.
- Latest data reveals that Seres Therapeutics reported Current Leases of $9.9 million as of Q3 2025, which was up 4.66% from $9.5 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Current Leases ranged from a high of $9.9 million in Q3 2025 and a low of $3.6 million during Q4 2022.
- Over the past 3 years, Seres Therapeutics' median Current Leases value was $8.7 million (recorded in 2024), while the average stood at $7.8 million.
- Its Current Leases has fluctuated over the past 5 years, first slumped by 45.52% in 2022, then soared by 84.64% in 2024.
- Quarterly analysis of 5 years shows Seres Therapeutics' Current Leases stood at $6.6 million in 2021, then plummeted by 45.52% to $3.6 million in 2022, then surged by 55.15% to $5.6 million in 2023, then spiked by 55.25% to $8.7 million in 2024, then rose by 18.86% to $9.9 million in 2025.
- Its Current Leases was $9.9 million in Q3 2025, compared to $9.5 million in Q2 2025 and $9.0 million in Q1 2025.